Previous close | 27.53 |
Open | 27.53 |
Bid | 21.65 |
Ask | 23.80 |
Strike | 110.00 |
Expiry date | 2025-01-17 |
Day's range | 27.53 - 27.53 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect™ Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key Insights Significantly high institutional ownership implies Medtronic's stock price is sensitive to their trading...